Menu
Not yet recruiting NCT07289750

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

Phase IV Interventional T2DM MAFLD

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: alogliptin and actoplus met, actoplus met.
Who it may be relevant to
Registry conditions: T2DM, MAFLD. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease

Overview

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Interventions

  • Drug alogliptin and actoplus met
    combination of alogliptin and actoplus met
  • Drug actoplus met
    actoplus met

Primary outcome measures

  • hemoglobin A1c [Time frame: 6 months of treatment]

Eligibility criteria

Inclusion criteria

  • Clinical diagnosis of T2DM
  • Clinical diagnosis of MAFLD
  • HbA1c: 6.5-9.5%
  • BMI: 19-35 kg/m2
  • No hypoglycemic drugs or insulin have been used within half a year

Exclusion criteria

  • Severe infections, surgeries and other emergency
  • Other types of diabetes
  • Severe cardiovascular, brain, liver and kidney disorders
  • Malignant tumor

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07289750 · KY-2025-242

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗